ÜbersichtsarbeitOpen Access · CC BY-NC 3.0
Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma
Oncolytic Virotherapy · 2017
DOI: 10.2147/ov.s100072 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Oncolytic Virotherapy, 2017. Verfasst von Hani M Babiker und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of Arizona Cancer Center. Die Arbeit wurde bisher 40-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Rigvirmelanomavirotherapy
Autor:innen und Institutionen
- University of Arizona Cancer Center.
- Department of Internal Medicine, University of Arizona, Tucson.
- Division of Hematology-Oncology, Mayo Clinic Cancer Center, Scottsdale, AZ; Department of Molecular Medicine, Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.
Zitieren
APA
Babiker, H. M., Riaz, I. B., Husnain, M., & Borad, M. J. (2017). Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma. Oncolytic Virotherapy. https://doi.org/10.2147/ov.s100072
Vancouver
Babiker HM, Riaz IB, Husnain M, Borad MJ. Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma. Oncolytic Virotherapy. 2017. doi:10.2147/ov.s100072
BibTeX
@article{Babiker2017,
author = {Babiker, Hani M and Riaz, Irbaz Bin and Husnain, Muhammad and Borad, Mitesh J},
title = {Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma},
journal = {Oncolytic Virotherapy},
year = {2017},
doi = {10.2147/ov.s100072}
}
EUVIMED